| Lung Non-Small Cell Carcinoma13 |
|---|
| EGFR L858R AND MET Amplification | Capmatinib + GefitinibCombination | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID11408A 73-year old male (non-smoker) with advanced non-small-cell lung cancer (NSCLC) was found to have EGFR L858R mutation and MET amplification. The patient had a dramatic response to erlotinib and crizo… (full text at CIViC) PMID 31864558 · Gainor et al., 2020 · Open in CIViC | civic |
| EGFR Mutation AND ( MET Amplification OR MET Overexpression ) | Gefitinib + TepotinibCombination | Predictive | B | Supports Sensitivity Response | 2 | submitted | EID11456This phase 1b/2, multicentre, randomized clinical trial was conducted on the combination of tepotinib and gefitinib on patients with MET overexpression or MET amplification that showed resistance to E… (full text at CIViC) PMID 32479794 · Wu et al., 2020 · Open in CIViC | civic |
| MET Amplification | Capmatinib | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID8849In a phase 2 trial, a total of 364 patients with non-small cell lung cancer and MET alterations received the MET inhibitor Capmatinib after assignment to cohorts based on prior treatment and type of M… (full text at CIViC) PMID 32877583 · Wolf et al., 2020 · Open in CIViC | civic |
| MET Amplification | Crizotinib | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID7502In a phase II trial patients with NSCLC harboring with MET amplification or MET exon 14 mutations were treated with multikinase inhibitor crizotinib.
MET amplification was defined as MET/CEP7 ration >… (full text at CIViC) PMID 31416808 · Landi et al., 2019 · Open in CIViC | civic |
| MET Amplification | Crizotinib | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID7639Patients with non-small cell lung carcinoma harboring MET alterations were treated with crizotinib.
MET amplification was defined as more than or equal to 6 copies.
The response rate at 2 cycles in pa… (full text at CIViC) PMID 31584608 · Moro-Sibilot et al., 2019 · Open in CIViC | civic |
| MET Amplification | Crizotinib | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID735A case-study of an ALK-negative patient with MET amplification (MET/CEP7 ratio >5.0) who achieved a durable partial response to MET/ALK-inhibitor crizotinib. PMID 21623265 · Ou et al., 2011 · Open in CIViC | civic |
| MET Amplification | Crizotinib | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID1713Case report of two patients with MET amplification (MET:CEP7 ratio ≥5) and no concomitant MET exon 14 deletion. A response to crizotinib was observed in both cases suggesting that MET amplification ma… (full text at CIViC) PMID 27664533 · Caparica et al., 2017 · Open in CIViC | civic |
| MET Amplification | Crizotinib | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID15662 MET amplified NSCLC cell lines (EBC-1 and H1993), as well as 2 EGFR mutant and 2 MET and EGFR wild type cell lines were treated with ALK and MET inhibitor crizotinib, and the MET amplified cells had… (full text at CIViC) PMID 21716144 · Tanizaki et al., 2011 · Open in CIViC | civic |
| MET Amplification | Gefitinib | Predictive | D | Supports Resistance | 4 | accepted | EID733In this study a gefitinib-sensitive cell-line (HCC827), acquired gefitinib resistance (HCC827 GR) by a focal amplification of MET. Resistance was conferred by the MET amplification driving ERBB3 (HER… (full text at CIViC) PMID 17463250 · Engelman et al., 2007 · Open in CIViC | civic |
| MET Amplification AND MET Splice Site (c.3028G>A) | Crizotinib | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID109564-year old female (non-smoker) was diagnosed with NSCLC. A c.3028 G->A mutation was identified in exon 14 resulting in exon 14 skipping. Further, amplification of the MET gene was observed. The patie… (full text at CIViC) PMID 26729443 · Awad et al., 2016 · Open in CIViC | civic |
| MET Amplification OR MET Exon 14 Skipping Mutation | (prognostic) | Prognostic | B | Supports Poor Outcome | 5 | submitted | EID11387A study of 687 patients with non-small-cell lung cancer were tested for MET exon splicing mutation or MET amplification. Univariable analysis showed that shorter overall disease-specific survival was … (full text at CIViC) PMID 26847053 · Tong et al., 2016 · Open in CIViC | civic |
| MET Amplification OR MET Exon 14 Skipping Mutation | Capmatinib | Predictive | B | Supports Sensitivity Response | 2 | submitted | EID11458Twenty patients with advanced non-small-cell lung cancer (NSCLC) with MET amplification or MET exon 14 skipping mutations were enrolled in this phase II clinical trial. All patients first received cri… (full text at CIViC) PMID 33545388 · Dagogo-Jack et al., 2021 · Open in CIViC | civic |
| NOT MET Amplification AND MET Exon 14 Skipping Mutation | Cabozantinib + CrizotinibSequential | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID11390A 65-year old white male (non-smoker) developed recurrent metastatic NSCLC 17 months after lobectomy for stage IA disease. Genomic profiling showed MET exon 14 skipping mutation without MET amplificat… (full text at CIViC) PMID 27693535 · Klempner et al., 2017 · Open in CIViC | civic |